Patent oral film market?

What is the Patent Oral Film Market?

The patent oral film market refers to pharmaceutical products that are protected by patents, which are film-coated oral tablets or films designed for rapid dissolution in the mouth without the need for water. These products aim to provide quick and easy medication delivery to patients, often used for sublingual absorption.

Why is Patent Exclusivity Expired So Quickly?

Patent exclusivity for oral films often expires 3-5 years after approval from the FDA [1], allowing generic or biosimilar versions to enter the market, which in turn accelerates competition and drives down prices. For instance, the patent expiration for Onglyza, a medication used to treat type 2 diabetes, was in 2017 [2], allowing generics to enter the market shortly after.

Who Makes Patent Oral Films?

Companies like Eli Lilly, Novartis, Pfizer, and AstraZeneca are among the major players in the patent oral film market. However, there are many other manufacturers offering similar products, which can complicate the regulatory and legal landscape. For example, in the case of Onglyza, multiple generic manufacturers have entered the market to offer competing versions [3].

Can Biosimilars Enter the Market Before Patent Expiry?

While patent exclusivity provides protection for a certain period, biosimilars are not subject to the same patent regulations. Biosimilars can enter the market upon regulatory approval, which may occur faster than patent expiration, further increasing competition in the market.

What are Key Patent Expirations in the Oral Film Market?

Patent expires for several oral film-based medications in the near future. According to DrugPatentWatch.com, the following notable patents are set to expire by 2026: [4]

- XIGDUO XR (dapagliflozin+metformin): January 2026
- OLYSIO (ledipasvir): April 2026
- ORKAMBI (lumacaftor+ivacaftor): January 2026

Clinical Implications and Patient Concerns

From a patient perspective, the patent oral film market may offer benefits like increased access to medications due to generics and biosimilars. However, regulatory scrutiny and ongoing legal challenges may impact the availability and pricing of certain medications.

Sources:

[1] FDA.gov - Orally Disintegrating Tablets: FDA Guidance for Industry.

[2] DrugPatentWatch.com - Patent Expiration for Onglyza.

[3] RxList.com - Onglyza Prescribing Information.

[4] DrugPatentWatch.com - Upcoming Expiring Patents.